Je was op zoek naar: proteasome (Maltees - Engels)

erlotinib u inibituri ta’ proteasome
erlotinib and proteasome inhibitors

bortezomib huwa inibitur tal-proteasome.
bortezomib is a proteasome inhibitor.

bortezomib huwa selettiv ħafna għall-proteasome.
bortezomib is highly selective for the proteasome.

mekkaniżmu kif jaħdem bortezomib huwa inibitur tal- proteasome.
mechanism of action bortezomib is a proteasome inhibitor.

26s proteasome hija proteina komposta kbira li tiddegrada proteini ubikwitinati.
the 26s proteasome is a large protein complex that degrades ubiquitinated proteins.

metaboliti deboronati permezz ta’ bortezomib mhumiex attivi bħala inibituri proteasome 26s.
deboronated-bortezomib metabolites are inactive as 26s proteasome inhibitors.

is- sustanza attiva f’ velcade, bortezomib, hija inibitur tal- proteasome.
the active substance in velcade, bortezomib, is a proteasome inhibitor.

is-sustanza attiva f'bortezomib sun, bortezomib, hija inibitur ta’ proteasome.
the active substance in bortezomib sun, bortezomib, is a proteasome inhibitor.

billi timblokka s-sistema tal-proteasome, tikkawża l-mewt taċ-ċellola.
blocking the proteasome system causes the cell to die.

velcade fih is-sustanza attiva bortezomib, hekk imsejjaħ ‘impeditur ta’ proteasome’.
velcade contains the active substance bortezomib, a so-called ‘proteasome inhibitor’.

bortezomib sun fih is-sustanza attiva bortezomib, hekk imsejjaħ ‘impeditur ta’ proteasome’.
bortezomib sun contains the active substance bortezomib, a so-called ‘proteasome inhibitor’.

bortezomib accord fih is-sustanza attiva bortezomib, hekk imsejjaħ ‘impeditur ta’ proteasome’.
bortezomib accord contains the active substance bortezomib, a so-called ‘proteasome inhibitor’.

huwa msawwar apposta biex jinibixxi l- attività li tixbaħ dik ta ’ chymotrypsin minn 26s proteasome f' ċelluli mammali.
it is specifically designed to inhibit the chymotrypsin-like activity of the 26s proteasome in mammalian cells.

il-proteasome hi sistema fi ħdan iċ-ċelloli li tkisser il-proteini meta ma jkunux qed jiffunzjonaw sewwa jew mhux meħtieġa aktar.
the proteasome is a system within the cells that breaks down proteins when they are damaged or no longer needed.

id-dożaġġ ikkombinat ma’ lenalidomide u dexamethasone ma kellu l-ebda effett fuq l-inibizzjoni tal-proteasome.
combination dosing with lenalidomide and dexamethasone did not affect proteasome inhibition.

din timblokka l- proteasome, li hija sistema fiċ-ċelloli li tkisser il-proteini meta ma jkunx hemm il-ħtieġa għalihom.
it blocks proteasome, which is a system in cells that breaks down proteins that are no longer needed.

dan ifisser li timblokka l- proteasome, li hija s-sistema fiċ-ċelloli li tkisser il-proteini meta dawn ma jkunx għad hemm bżonnhom.
this means that it blocks the proteasome, which is a system within the cells that breaks down proteins when they are no longer needed.

l-inibizzjoni tal-proteasome inżammet għal ≥ 48 siegħa wara l-ewwel doża ta’ carfilzomib għal kull ġimgħa ta’ dożaġġ.
proteasome inhibition was maintained for ≥ 48 hours following the first dose of carfilzomib for each week of dosing.

l-inibizzjoni tal-26s proteasome iżomm milli sseħħ din il-proteoliżi u taffettwa l-kaskati ta’ senjalazzjonijiet multipli fiċ-ċellula, li fl-aħħar mill-aħħar iwassal għall-mewt taċ-ċellula tal- kanċer.
inhibition of the 26s proteasome prevents this targeted proteolysis and affects multiple signalling cascades within the cell, ultimately resulting in cancer cell death.